

# Provident Pharmaceuticals



## Corporate Presentation

## Who we are

- Provident Pharmaceuticals is a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche and legacy pharmaceutical products and medical devices in specific therapeutic areas.
- Our company has been active since 2012, operating in the marketing of generic pharmaceutical products and of novel medical devices, with a presence in both the private sector and public hospitals.
- Our presence in the Greek market has ensured high quality medicinal products, of high therapeutic value, as well as substances that stand out in their pharmacologic class.

## Who we are (contd.)

- All products of the company are approved, produced, and distributed in accordance with current European standards and legislation.
- We are a full-service pharmaceutical company offering sales and marketing, regulatory services, market access, and distribution capabilities for product partnership opportunities.
- Amongst other areas, we are local market leaders in the muscle spasticity segment and very strong in HA for joints segment, some areas of oncology and additionally alimentary tract /metabolism.

## What we do

Our **mission** is to provide innovative **high quality medicines** that offer **therapeutic solutions** to a wide **range of conditions**.

In this effort we promote and support innovative ideas in collaboration with health providers.

## What we do (contd.)

Our business concept is **twofold:**

Acquiring well established, original or generic medicinal products from international pharmaceutical companies to be marketed mainly within Greece, Cyprus and the South Eastern Mediterranean.

We support international pharmaceutical companies in their endeavour to market and distribute pharmaceutical products and medical devices in this area.

# Current Products

Our current products fall under the following categories:

1. Cardio Vascular
2. Central Nervous System
3. Oncology
4. Vitamins (medical)
5. Medical Devices
6. Veterinary

# Current Products: Cardio Vascular

- **Ramisyn:** used to treat high blood pressure, heart failure, and to reduce the risk of cardiovascular events in patients with a history of heart attack, stroke, or peripheral artery disease.
- **Ramisyn Plus:** combination medication of Ramipril and hydrochlorothiazide to treat high blood pressure in patients who require both medications to control their blood pressure.
- **Minolip Plus:** used to lower cholesterol levels in the blood, helping reduce the risk of cardiovascular events in patients.

Brand/ Strength	Active Substance	Units per year*
Ramisyn 5mg/Tab	ramipril	60.000
Ramisyn Plus (5+25)mg/Tab	ramipril + HTC	30.000
Minolip Plus (10+10&20&40) mg/FC Tab	Atorvastatin+ ezetimibe	Launching Q1/2024

\*for F/Y 2022

# Current Products: Central Nervous System

- **Miorel** (*tab and oral*): used to treat muscle spasms and spasticity caused by conditions such as multiple sclerosis, cerebral palsy, and spinal cord injuries.
- **Adtreat**: used to improve memory and cognitive function in individuals with Alzheimer's disease.
- **Certorun**: used to treat depression, anxiety, and other mood disorders

Brand/ Strength	Active Substance	Units per year*
Miorel 10 mg/Tab	baclofen	180.000
Miorel Oral 10 mg/ml	baclofen	Launching Q2/2024
Adtreat 5&10 mg/Tab	donepezil	15.000
Certorun 50&100 mg/Caps	setraline	Launching Q3/2023

\*for F/Y 2022



# Current Products: Oncology

- **Dexa-Dose:** used to help manage certain symptoms associated with cancer and its treatment by reducing inflammation and swelling in the body, as well as suppressing the immune system.

Brand/ Strength	Active Substance	Units per year*
Dexa-dose 20 mg/5 ml	dexamethasone	15.000

\*for F/Y 2022

## Current Products: Vitamins (medical use)

- **DE3-Sole:** used to treat vitamin D deficiency helping the body absorb calcium and phosphorus
- **Calcifolin:** used to treat certain types of anaemia, as well as to counteract the toxic effects of some chemotherapy drugs.

Brand/ Strength	Active Substance	Units per year*
De3-Sole 25000IU /2.5ml	cholecalciferol	240.000
Calcifolin 15&25 mg/Tab	folinic acid	100.000

\*for F/Y 2022

## Current Products: Medical Devices

- **Promovia:** used as a treatment for various joint disorders, including osteoarthritis, improving mobility.
- **Playal:** used in the treatment of various joint disorders, with extra anti-inflammatory action.
- **Evryal:** used as a dermal filler for cosmetic purposes.
- **Kadermin:** used in reducing the risk of infection and promoting wound healing.

Brand/ Strength	Active Substance	Units per year*
Promovia (24,40,50, 60,80,100) mg/INJ	hyaluronic acid (orthopedic)	15.000
Playal (40,80) mg/INJ	hyaluronic acid + nicotinamide (orthopedic)	6.000
Evryal (hydrate, soft, medium, strong) INJ	cross linked hyaluronic acid (cosmetic)	6.000
Kadermin Nasal/Cream	Silver ions & Chlorhexidine (home use)	Launching Q3/2023

\*for F/Y 2022

# Current Products: Veterinary


- **Promovet:** used as a pharmaceutical excipient for veterinary practices.

Brand/ Strength	Active Substance	Units per year*
Promovet 3 ml/INJ	Carboxymethylcellulose sodium salt, crosscarmellose sodium chloride	Launching Q3/2023


\*for F/Y 2022

# Market Overview

## Greek Pharmaceutical Market



# Market Overview (contd.)



## Key Financial Information

- Between 2020 and 2021:
  - 31% Y/Y revenue growth
  - 33% Y/Y net profit growth
  - 33% Y/Y total assets growth
  - 34% Y/Y equity growth

# Key Performance Indicators

	<b>2021</b>	<b>2020</b>
Gross Profit Margin	55%	56%
Net Profit Margin	30%	29%
Return on Equity	297%	299%
Debt-to-Equity Ratio	10.95	9.99
Inventory Turnover Ratio	4.4	3.6